189 related articles for article (PubMed ID: 27627194)
21. Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers.
Lauring B; Liu Y; Li XS; Larson P; Moreau A; Farmer HF; Johnson-Levonas AO; Wagner JA; Lai E
J Clin Pharmacol; 2014 Jul; 54(7):765-75. PubMed ID: 24615657
[TBL] [Abstract][Full Text] [Related]
22. Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects.
Darpö B; Sager P; MacConell L; Cirincione B; Mitchell M; Han J; Huang W; Malloy J; Schulteis C; Shen L; Porter L
Br J Clin Pharmacol; 2013 Apr; 75(4):979-89. PubMed ID: 22882281
[TBL] [Abstract][Full Text] [Related]
23. Deferasirox does not induce QT/QTc-prolongation in healthy subjects.
Sechaud R; Dumortier T; Balez S
Int J Clin Pharmacol Ther; 2009 May; 47(5):321-7. PubMed ID: 19473594
[TBL] [Abstract][Full Text] [Related]
24. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.
Biftu T; Sinha-Roy R; Chen P; Qian X; Feng D; Kuethe JT; Scapin G; Gao YD; Yan Y; Krueger D; Bak A; Eiermann G; He J; Cox J; Hicks J; Lyons K; He H; Salituro G; Tong S; Patel S; Doss G; Petrov A; Wu J; Xu SS; Sewall C; Zhang X; Zhang B; Thornberry NA; Weber AE
J Med Chem; 2014 Apr; 57(8):3205-12. PubMed ID: 24660890
[TBL] [Abstract][Full Text] [Related]
25. Omarigliptin for the treatment of type 2 diabetes.
Tan X
Endocrine; 2016 Oct; 54(1):24-31. PubMed ID: 27372109
[TBL] [Abstract][Full Text] [Related]
26. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
[TBL] [Abstract][Full Text] [Related]
27. A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment.
Chacra A; Gantz I; Mendizabal G; Durlach L; O'Neill EA; Zimmer Z; Suryawanshi S; Engel SS; Lai E
Int J Clin Pract; 2017 Jun; 71(6):. PubMed ID: 28449320
[TBL] [Abstract][Full Text] [Related]
28. Evacetrapib at a supratherapeutic steady state concentration does not prolong QT in a thorough QT/QTc study in healthy participants.
Suico JG; Friedrich S; Krueger KA; Zhang W
J Cardiovasc Pharmacol Ther; 2014 May; 19(3):283-9. PubMed ID: 24271137
[TBL] [Abstract][Full Text] [Related]
29. The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: A systemic review and meta-analysis.
Wang X; Li X; Qie S; Zheng Y; Liu Y; Liu G
Medicine (Baltimore); 2018 Aug; 97(34):e11946. PubMed ID: 30142816
[TBL] [Abstract][Full Text] [Related]
30. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization.
Chen S; Min SS; Peppercorn A; Borland J; Lou Y; Song I; Fujiwara T; Piscitelli SC
Pharmacotherapy; 2012 Apr; 32(4):333-9. PubMed ID: 22422361
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P
Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934
[TBL] [Abstract][Full Text] [Related]
32. A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects.
German P; Mathias A; Brainard DM; Song Q; Ling J; Kearney BP
Clin Pharmacol Drug Dev; 2018 Aug; 7(6):641-651. PubMed ID: 29058821
[TBL] [Abstract][Full Text] [Related]
33. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.
Kori S; Kellerman DJ; Voloshko P; Haugen G
Clin Ther; 2012 Sep; 34(9):1920-8. PubMed ID: 22917853
[TBL] [Abstract][Full Text] [Related]
34. A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects.
Bloomfield DM; Krishna R; Hreniuk D; Hickey L; Ghosh K; Bergman AJ; Miller J; Gutierrez MJ; Stoltz R; Gottesdiener KM; Herman GA; Wagner JA
J Clin Pharmacol; 2009 Aug; 49(8):937-46. PubMed ID: 19602719
[TBL] [Abstract][Full Text] [Related]
35. Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam.
Das S; Armstrong J; Mathews D; Li J; Edeki T
J Clin Pharmacol; 2014 Mar; 54(3):331-40. PubMed ID: 24150927
[TBL] [Abstract][Full Text] [Related]
36. A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects.
Abbas R; Hug BA; Leister C; Sonnichsen D
Int J Cancer; 2012 Aug; 131(3):E304-11. PubMed ID: 22065400
[TBL] [Abstract][Full Text] [Related]
37. A Thorough QT Study to Evaluate the Effects of a Supratherapeutic Dose of Sertraline on Cardiac Repolarization in Healthy Subjects.
Abbas R; Riley S; LaBadie RR; Bachinsky M; Chappell PB; Crownover PH; Damle B
Clin Pharmacol Drug Dev; 2020 Apr; 9(3):307-320. PubMed ID: 31777203
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
[TBL] [Abstract][Full Text] [Related]
39. Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects.
McCrea J; Mostoller K; Mahon C; Liu C; Liu F; Zajic S; Panebianco D; Chakravarthy M; Brandquist C; Gutierrez M; Stoch SA
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):861-870. PubMed ID: 31175709
[TBL] [Abstract][Full Text] [Related]
40. Concentration-QTc Modeling of the DPP-4 Inhibitor HSK7653 in a First-in-Human Study of Chinese Healthy Volunteers.
Wang X; Liu H; Cui C; Niu X; Li H; Niu S; Yan P; Wu N; Li F; Wu Q; Chen K; Hu B; Liu D
Clin Pharmacol Drug Dev; 2024 Jul; 13(7):716-728. PubMed ID: 38757550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
